Bachem

Bachem, a peptides and oligonucleotides provider, announced Anne-Kathrin Stoller as the new CEO, effective January 1, 2026. Stoller, currently Head of Bachem Americas, succeeds Thomas Meier after his 30-year tenure. The appointment reflects Bachem’s strategic succession planning, leveraging Stoller’s deep understanding of the company and the biopharmaceutical market. Bachem is poised to capitalize on the growth of the peptides and oligonucleotides market under her leadership.